A	O
quantitative	O
method	B:C0025663
for	O
the	O
assessment	O
of	O
dysarthrophonia	O
in	O
myasthenia	O
gravis	I:C0026896
.	O

A	O
quantitative	O
method	O
for	O
the	O
assessment	B:C0220825
of	O
dysarthrophonia	O
in	O
myasthenia	O
gravis	I:C0026896
.	O

A	O
quantitative	O
method	O
for	O
the	O
assessment	O
of	O
dysarthrophonia	B:C1457887
in	O
myasthenia	O
gravis	I:C0026896
.	O

A	O
quantitative	O
method	O
for	O
the	O
assessment	O
of	O
dysarthrophonia	O
in	O
myasthenia	B:C0026896
gravis	I:C0026896
.	O

Speech	B:C0037817
and	O
voice	O
symptomatology	O
(	O
dysarthrophonia	O
)	O
are	O
often	O
reported	O
by	O
patients	O
with	O
myasthenia	O
gravis	I:C0026896
(	O
myasthenia	O
gravis	I:C0026896
)	O
.	O

Speech	O
and	O
voice	B:C0042939
symptomatology	O
(	O
dysarthrophonia	O
)	O
are	O
often	O
reported	O
by	O
patients	O
with	O
myasthenia	O
gravis	I:C0026896
(	O
myasthenia	O
gravis	I:C0026896
)	O
.	O

Speech	O
and	O
voice	O
symptomatology	B:C1457887
(	O
dysarthrophonia	O
)	O
are	O
often	O
reported	O
by	O
patients	O
with	O
myasthenia	O
gravis	I:C0026896
(	O
myasthenia	O
gravis	I:C0026896
)	O
.	O

Speech	O
and	O
voice	O
symptomatology	O
(	O
dysarthrophonia	B:C1457887
)	O
are	O
often	O
reported	O
by	O
patients	O
with	O
myasthenia	O
gravis	I:C0026896
(	O
myasthenia	O
gravis	I:C0026896
)	O
.	O

Speech	O
and	O
voice	O
symptomatology	O
(	O
dysarthrophonia	O
)	O
are	O
often	O
reported	O
by	O
patients	O
with	O
myasthenia	B:C0026896
gravis	I:C0026896
(	O
myasthenia	O
gravis	I:C0026896
)	O
.	O

Speech	O
and	O
voice	O
symptomatology	O
(	O
dysarthrophonia	O
)	O
are	O
often	O
reported	O
by	O
patients	O
with	O
myasthenia	O
gravis	I:C0026896
(	O
myasthenia	B:C0026896
gravis	I:C0026896
)	O
.	O

Quantitative	O
methods	B:C0025663
for	O
the	O
assessment	O
of	O
dysarthrοphonia	O
could	O
facilitate	O
the	O
evaluation	O
of	O
these	O
common	O
myasthenia	O
gravis	I:C0026896
symptoms	O
.	O

Quantitative	O
methods	O
for	O
the	O
assessment	B:C0220825
of	O
dysarthrοphonia	O
could	O
facilitate	O
the	O
evaluation	O
of	O
these	O
common	O
myasthenia	O
gravis	I:C0026896
symptoms	O
.	O

Quantitative	O
methods	O
for	O
the	O
assessment	O
of	O
dysarthrοphonia	B:C1457887
could	O
facilitate	O
the	O
evaluation	O
of	O
these	O
common	O
myasthenia	O
gravis	I:C0026896
symptoms	O
.	O

Quantitative	O
methods	O
for	O
the	O
assessment	O
of	O
dysarthrοphonia	O
could	O
facilitate	O
the	O
evaluation	B:C0220825
of	O
these	O
common	O
myasthenia	O
gravis	I:C0026896
symptoms	O
.	O

Quantitative	O
methods	O
for	O
the	O
assessment	O
of	O
dysarthrοphonia	O
could	O
facilitate	O
the	O
evaluation	O
of	O
these	O
common	O
myasthenia	B:C0026896
gravis	I:C0026896
symptoms	O
.	O

Quantitative	O
methods	O
for	O
the	O
assessment	O
of	O
dysarthrοphonia	O
could	O
facilitate	O
the	O
evaluation	O
of	O
these	O
common	O
myasthenia	O
gravis	I:C0026896
symptoms	B:C1457887
.	O

The	O
goal	B:C0018017
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
phonatory	O
(	O
sustained	O
phonation	O
and	O
reading	O
)	O
and	O
speech	O
(	O
diadochokinesis	O
)	O
function	O
in	O
myasthenia	O
gravis	I:C0026896
patients	O
using	O
quantitative	O
measures	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
phonatory	B:C0031577
(	O
sustained	O
phonation	O
and	O
reading	O
)	O
and	O
speech	O
(	O
diadochokinesis	O
)	O
function	O
in	O
myasthenia	O
gravis	I:C0026896
patients	O
using	O
quantitative	O
measures	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
phonatory	O
(	O
sustained	O
phonation	B:C0031577
and	O
reading	O
)	O
and	O
speech	O
(	O
diadochokinesis	O
)	O
function	O
in	O
myasthenia	O
gravis	I:C0026896
patients	O
using	O
quantitative	O
measures	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
phonatory	O
(	O
sustained	O
phonation	O
and	O
reading	O
)	O
and	O
speech	B:C0037817
(	O
diadochokinesis	O
)	O
function	O
in	O
myasthenia	O
gravis	I:C0026896
patients	O
using	O
quantitative	O
measures	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
phonatory	O
(	O
sustained	O
phonation	O
and	O
reading	O
)	O
and	O
speech	O
(	O
diadochokinesis	B:C0278157
)	O
function	O
in	O
myasthenia	O
gravis	I:C0026896
patients	O
using	O
quantitative	O
measures	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
phonatory	O
(	O
sustained	O
phonation	O
and	O
reading	O
)	O
and	O
speech	O
(	O
diadochokinesis	O
)	O
function	B:C0031843
in	O
myasthenia	O
gravis	I:C0026896
patients	O
using	O
quantitative	O
measures	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
phonatory	O
(	O
sustained	O
phonation	O
and	O
reading	O
)	O
and	O
speech	O
(	O
diadochokinesis	O
)	O
function	O
in	O
myasthenia	B:C0026896
gravis	I:C0026896
patients	O
using	O
quantitative	O
measures	O
.	O

The	O
voice	B:C0042939
/	O
speech	O
of	O
12	O
myasthenia	O
gravis	I:C0026896
patients	O
(	O
7	O
with	O
anti-AchR	O
and	O
5	O
with	O
anti-MuSK	O
antibodies	I:C3203598
)	O
and	O
24	O
age	O
-	O
matched	O
healthy	O
controls	O
was	O
recorded	O
and	O
analyzed	O
using	O
electroglottography	O
(	O
electroglottography	O
)	O
and	O
speech	O
acoustics	O
.	O

The	O
voice	O
/	O
speech	B:C0037817
of	O
12	O
myasthenia	O
gravis	I:C0026896
patients	O
(	O
7	O
with	O
anti-AchR	O
and	O
5	O
with	O
anti-MuSK	O
antibodies	I:C3203598
)	O
and	O
24	O
age	O
-	O
matched	O
healthy	O
controls	O
was	O
recorded	O
and	O
analyzed	O
using	O
electroglottography	O
(	O
electroglottography	O
)	O
and	O
speech	O
acoustics	O
.	O

The	O
voice	O
/	O
speech	O
of	O
12	O
myasthenia	B:C0026896
gravis	I:C0026896
patients	O
(	O
7	O
with	O
anti-AchR	O
and	O
5	O
with	O
anti-MuSK	O
antibodies	I:C3203598
)	O
and	O
24	O
age	O
-	O
matched	O
healthy	O
controls	O
was	O
recorded	O
and	O
analyzed	O
using	O
electroglottography	O
(	O
electroglottography	O
)	O
and	O
speech	O
acoustics	O
.	O

The	O
voice	O
/	O
speech	O
of	O
12	O
myasthenia	O
gravis	I:C0026896
patients	O
(	O
7	O
with	O
anti-AchR	B:C0236516
and	O
5	O
with	O
anti-MuSK	O
antibodies	I:C3203598
)	O
and	O
24	O
age	O
-	O
matched	O
healthy	O
controls	O
was	O
recorded	O
and	O
analyzed	O
using	O
electroglottography	O
(	O
electroglottography	O
)	O
and	O
speech	O
acoustics	O
.	O

The	O
voice	O
/	O
speech	O
of	O
12	O
myasthenia	O
gravis	I:C0026896
patients	O
(	O
7	O
with	O
anti-AchR	O
and	O
5	O
with	O
anti-MuSK	B:C3203598
antibodies	I:C3203598
)	O
and	O
24	O
age	O
-	O
matched	O
healthy	O
controls	O
was	O
recorded	O
and	O
analyzed	O
using	O
electroglottography	O
(	O
electroglottography	O
)	O
and	O
speech	O
acoustics	O
.	O

The	O
voice	O
/	O
speech	O
of	O
12	O
myasthenia	O
gravis	I:C0026896
patients	O
(	O
7	O
with	O
anti-AchR	O
and	O
5	O
with	O
anti-MuSK	O
antibodies	I:C3203598
)	O
and	O
24	O
age	O
-	O
matched	O
healthy	O
controls	O
was	O
recorded	O
and	O
analyzed	O
using	O
electroglottography	B:C1096366
(	O
electroglottography	O
)	O
and	O
speech	O
acoustics	O
.	O

The	O
voice	O
/	O
speech	O
of	O
12	O
myasthenia	O
gravis	I:C0026896
patients	O
(	O
7	O
with	O
anti-AchR	O
and	O
5	O
with	O
anti-MuSK	O
antibodies	I:C3203598
)	O
and	O
24	O
age	O
-	O
matched	O
healthy	O
controls	O
was	O
recorded	O
and	O
analyzed	O
using	O
electroglottography	O
(	O
electroglottography	B:C1096366
)	O
and	O
speech	O
acoustics	O
.	O

For	O
the	O
analysis	O
of	O
voice	B:C0042939
,	O
the	O
variables	O
that	O
were	O
found	O
to	O
distinguish	O
myasthenia	O
gravis	I:C0026896
patients	O
compared	O
to	O
healthy	O
controls	O
were	O
a	O
higher	O
average	O
fundamental	O
frequency	O
(	O
P<	O
0.05	O
)	O
,	O
a	O
higher	O
standard	O
deviation	O
of	O
the	O
average	O
fundamental	O
frequency	O
(	O
P<	O
0.001	O
)	O
,	O
a	O
higher	O
mean	O
fundamental	O
frequency	O
of	O
the	O
vibrating	O
vocal	I:C0042930
folds	I:C0042930
(	O
P<	O
0.005	O
)	O
and	O
a	O
higher	O
fundamental	O
frequency	O
range	O
(	O
P<	O
0.005	O
)	O
.	O

For	O
the	O
analysis	O
of	O
voice	O
,	O
the	O
variables	O
that	O
were	O
found	O
to	O
distinguish	O
myasthenia	B:C0026896
gravis	I:C0026896
patients	O
compared	O
to	O
healthy	O
controls	O
were	O
a	O
higher	O
average	O
fundamental	O
frequency	O
(	O
P<	O
0.05	O
)	O
,	O
a	O
higher	O
standard	O
deviation	O
of	O
the	O
average	O
fundamental	O
frequency	O
(	O
P<	O
0.001	O
)	O
,	O
a	O
higher	O
mean	O
fundamental	O
frequency	O
of	O
the	O
vibrating	O
vocal	I:C0042930
folds	I:C0042930
(	O
P<	O
0.005	O
)	O
and	O
a	O
higher	O
fundamental	O
frequency	O
range	O
(	O
P<	O
0.005	O
)	O
.	O

For	O
the	O
analysis	O
of	O
voice	O
,	O
the	O
variables	O
that	O
were	O
found	O
to	O
distinguish	O
myasthenia	O
gravis	I:C0026896
patients	O
compared	O
to	O
healthy	O
controls	O
were	O
a	O
higher	O
average	O
fundamental	O
frequency	O
(	O
P<	O
0.05	O
)	O
,	O
a	O
higher	O
standard	O
deviation	O
of	O
the	O
average	O
fundamental	O
frequency	O
(	O
P<	O
0.001	O
)	O
,	O
a	O
higher	O
mean	O
fundamental	O
frequency	O
of	O
the	O
vibrating	B:C0042930
vocal	I:C0042930
folds	I:C0042930
(	O
P<	O
0.005	O
)	O
and	O
a	O
higher	O
fundamental	O
frequency	O
range	O
(	O
P<	O
0.005	O
)	O
.	O

The	O
analysis	O
of	O
diadochokinesis	B:C0278157
showed	O
that	O
myasthenia	O
gravis	I:C0026896
patients	O
had	O
a	O
higher	O
mean	O
duration	O
of	O
the	O
silent	O
interval	O
between	O
a	O
series	O
of	O
repetitive	O
/	O
pa	O
/	O
syllables	O
(	O
P<	O
0.05	O
)	O
,	O
of	O
the	O
sound	O
/t/	O
(	O
P=0.05	O
)	O
and	O
of	O
the	O
silent	O
interval	O
between	O
a	O
series	O
of	O
repetitive	O
/	O
ka	O
/	O
syllables	O
(	O
P<	O
0.05	O
)	O
.	O

The	O
analysis	O
of	O
diadochokinesis	O
showed	O
that	O
myasthenia	B:C0026896
gravis	I:C0026896
patients	O
had	O
a	O
higher	O
mean	O
duration	O
of	O
the	O
silent	O
interval	O
between	O
a	O
series	O
of	O
repetitive	O
/	O
pa	O
/	O
syllables	O
(	O
P<	O
0.05	O
)	O
,	O
of	O
the	O
sound	O
/t/	O
(	O
P=0.05	O
)	O
and	O
of	O
the	O
silent	O
interval	O
between	O
a	O
series	O
of	O
repetitive	O
/	O
ka	O
/	O
syllables	O
(	O
P<	O
0.05	O
)	O
.	O

No	O
statistical	O
differences	O
were	O
found	O
in	O
any	O
of	O
these	O
variables	O
between	O
the	O
myasthenia	B:C0026896
gravis	I:C0026896
subgroups	O
with	O
anti-AchR	O
or	O
anti-MuSK	O
antibodies	I:C3203598
.	O

No	O
statistical	O
differences	O
were	O
found	O
in	O
any	O
of	O
these	O
variables	O
between	O
the	O
myasthenia	O
gravis	I:C0026896
subgroups	B:C1515021
with	O
anti-AchR	O
or	O
anti-MuSK	O
antibodies	I:C3203598
.	O

No	O
statistical	O
differences	O
were	O
found	O
in	O
any	O
of	O
these	O
variables	O
between	O
the	O
myasthenia	O
gravis	I:C0026896
subgroups	O
with	O
anti-AchR	B:C0236516
or	O
anti-MuSK	O
antibodies	I:C3203598
.	O

No	O
statistical	O
differences	O
were	O
found	O
in	O
any	O
of	O
these	O
variables	O
between	O
the	O
myasthenia	O
gravis	I:C0026896
subgroups	O
with	O
anti-AchR	O
or	O
anti-MuSK	B:C3203598
antibodies	I:C3203598
.	O

This	O
study	B:C2603343
demonstrates	O
that	O
non-invasive	O
physiological	O
methods	O
(	O
electroglottography	O
and	O
speech	O
acoustics	O
)	O
offer	O
essential	O
tools	O
for	O
the	O
assessment	O
of	O
dysarthrophonia	O
in	O
myasthenia	O
gravis	I:C0026896
patients	O
.	O

This	O
study	O
demonstrates	O
that	O
non-invasive	O
physiological	O
methods	B:C0025663
(	O
electroglottography	O
and	O
speech	O
acoustics	O
)	O
offer	O
essential	O
tools	O
for	O
the	O
assessment	O
of	O
dysarthrophonia	O
in	O
myasthenia	O
gravis	I:C0026896
patients	O
.	O

This	O
study	O
demonstrates	O
that	O
non-invasive	O
physiological	O
methods	O
(	O
electroglottography	B:C1096366
and	O
speech	O
acoustics	O
)	O
offer	O
essential	O
tools	O
for	O
the	O
assessment	O
of	O
dysarthrophonia	O
in	O
myasthenia	O
gravis	I:C0026896
patients	O
.	O

This	O
study	O
demonstrates	O
that	O
non-invasive	O
physiological	O
methods	O
(	O
electroglottography	O
and	O
speech	O
acoustics	O
)	O
offer	O
essential	O
tools	O
for	O
the	O
assessment	B:C0220825
of	O
dysarthrophonia	O
in	O
myasthenia	O
gravis	I:C0026896
patients	O
.	O

This	O
study	O
demonstrates	O
that	O
non-invasive	O
physiological	O
methods	O
(	O
electroglottography	O
and	O
speech	O
acoustics	O
)	O
offer	O
essential	O
tools	O
for	O
the	O
assessment	O
of	O
dysarthrophonia	B:C1457887
in	O
myasthenia	O
gravis	I:C0026896
patients	O
.	O

This	O
study	O
demonstrates	O
that	O
non-invasive	O
physiological	O
methods	O
(	O
electroglottography	O
and	O
speech	O
acoustics	O
)	O
offer	O
essential	O
tools	O
for	O
the	O
assessment	O
of	O
dysarthrophonia	O
in	O
myasthenia	B:C0026896
gravis	I:C0026896
patients	O
.	O

